Arovella Newsletter May 2025
We are pleased to share an update that reflects the significant momentum and strategic advancements at Arovella Therapeutics over the past few months. Our unwavering commitment to revolutionising cancer treatment through innovative cell therapies is yielding tangible results, and we are excited about the path ahead.
Highlights:
Completed $15M Placement ensuring the company is fully funded to complete phase 1 enrolment and generate clinical data
Continued advancing ALA-101 towards a first-in-human clinical trial by moving manufacturing to GMP suites
Continued clinical readiness by appointing Jacqui Cumming as Senior Director of Clinical Development
Entered into a sponsored research agreement with The University of North Carolina and appointed Dr Clinton Heinze to drive the research
